Major depressive disorder: why does it affect women more?
Major depressive disorder (MDD) is a common mental health disorder that affects more than 264 million people globally, and it disproportionately affects women.
mental health conditions
Novartis to acquire neuroscience firm Cadent Therapeutics for up to $770m
Novartis has entered into a definitive agreement to acquire all of the outstanding capital stock...
Biogen and Sage Therapeutics to co-develop depression and tremor therapies
Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor...
Twitter round-up: Neurology tweets – David Perlmutter’s tweet on meditation most popular in December 2019
Pharmaceutical Technology lists ten of the most popular tweets on neurology in December 2019, based on data from GlobalData’s Influencer...
Can controlled substances become the new standard of care for psychiatric disorders?
Disorders such as depression and anxiety have long been treated with drugs that are associated with side effects such as blurred vision, headaches, diarrhoea, sexual dysfunction, insomnia and tremors. First-line…
Global post-traumatic stress disorder market set to reach US$1.2 billion by 2028, says GlobalData
Post-traumatic stress disorder (PTSD) is a psychiatric disorder that occurs in those who have experienced or witnessed a traumatic event. This disorder commonly affects soldiers after deployment, and can also…
UK Government invests £35m into researching adolescent mental health
The UK Government has launched a research project into understanding the causes of mental health problems in teenagers and young adults, including the genetics and societal influences underpinning why some…
ViiV unveils emotional challenges related to HIV ART treatment
GSK’s ViiV Healthcare has presented results from its Positive Perspectives study examining the emotional challenges and burden of human immunodeficiency virus (HIV) antiretroviral therapy (ART) on people living with the…
Takeda and Lundbeck’s Trintellix approved in Japan for depression
Takeda has announced that its drug Trintellix (vortioxetine) has been approved by the Japanese Ministry of Health, Labour and Welfare for the treatment of depression and depressed state. Danish company…
Can sleep disruptions lead to Alzheimer’s disease?
In the second of a three-part series of articles ahead of World Alzheimer’s Day (on 21 September), it's worth considering that Alzheimer’s Disease (AD) is the most prevalent neurodegenerative disorder…
